Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis BYao‐Chun Hsu, Mindie H. Nguyen, Grace Lai‐Hung Wong et al.|The American Journal of Gastroenterology|2019Cited by 102
Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral TherapyHwai‐I Yang, Mindie H. Nguyen, Ming‐Lun Yeh et al.|The Journal of Infectious Diseases|2019Cited by 101
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patientsMatt Liu, Jia‐Horng Kao, Tai‐Chung Tseng et al.|Hepatology International|2021Cited by 33
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision MedicineJiyoon Park, Ming‐Lung Yu, An K. Le et al.|Clinical Gastroenterology and Hepatology|2021Cited by 16
One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatmentTai‐Chung Tseng, Jia‐Horng Kao, Jonggi Choi et al.|Hepatology International|2021Cited by 11